ArticleHand (New York, N.Y.)2010
Tacrolimus (FK506): Safety and Applications in Reconstructive Surgery.
Article in Hand (New York, N.Y.), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 34 citations in OpenAlex.
- Maximizing Neurovascular Outcomes of Facial Transplantation: A Comprehensive Review.Clinical anatomy (New York, N.Y.) · 2026Review
- Injectable Thermoresponsive Dual Nanocarrier Hydrogel for Local Tacrolimus Delivery with a Two-Phase Release Profile.Pharmaceutics · 2026Article
- A novel strategy for spinal cord reconstruction via vascularized allogeneic spinal cord transplantation combine spinal cord fusion.CNS neuroscience & therapeutics · 2024Article
- Neuromodulators can promote nerve regeneration and accelerate functional recovery after peripheral nerve injury: A systematic review.Journal of orthopaedics · 2024Review
- Localization of drug biodistribution in a 3D-bioengineered subcutaneous neovascularized microenvironment.Materials today. Bio · 2022Article
- Mesenchymal stem cells and local tacrolimus delivery synergistically enhance neurite extension.Biotechnology and bioengineering · 2021Article
- FKBP22 from the psychrophilic bacterium Shewanella sp. SIB1 selectively binds to the reduced state of insulin to prevent its aggregation.Cell stress & chaperones · 2021Article
- Advances in the repair of segmental nerve injuries and trends in reconstruction.Muscle & nerve · 2020Review
- Restoration of Neurological Function Following Peripheral Nerve Trauma.International journal of molecular sciences · 2020Review
- Rational design of a Kv1.3 channel-blocking antibody as a selective immunosuppressant.Proceedings of the National Academy of Sciences of the United States of America · 2016Article
- Application of topical pharmacological agents at the site of peripheral nerve injury and methods used for evaluating the success of the regenerative process.Journal of orthopaedic surgery and research · 2014Review
- Rapamycin promotes Schwann cell migration and nerve growth factor secretion.Neural regeneration research · 2014Article
- Tissue engineered constructs for peripheral nerve surgery.European surgery : ACA : Acta chirurgica Austriaca · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tacrolimus (FK506) is a macrolide immunosuppressive drug that is approved for the prevention of allograft rejection. It is a standard component of immunosuppressive regimens currently in use for organ and reconstructive tissue transplants. The experimental literature has demonstrated potential efficacy in the management of other diseases for which transplantation does not play a role. The ability of tacrolimus to modulate the immune system and inhibit T cell activation provides a potential benefit for the treatment of disorders in which autoimmune phenomena are central to their pathogenesis such as rheumatoid arthritis and inflammatory bowel disease. Tacrolimus also has well-established neuroprotective and neuroregenerative properties through both similar and different mechanisms that have been extensively demonstrated in both small and large animal models. However, as a potent immunosuppressive agent, it can cause serious adverse effects, some of which are irreversible and potentially life threatening. This article reviews its safety under different therapeutic requirements and applications in both allogeneic and autogenous tissue reconstruction.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.